2 results
Approved WMOPending
The primary objective of the study is to assess the pharmacokinetics (PK) of PXL770 in AMN subjects at the dose of 500mg once daily (OD) and 250mg twice daily (BID) after 4 weeks of treatment.
Approved WMOPending
To test whether tACS in a theta frequency enhances extinction of physiological stress responses to exposure to anxiety- or trauma-related stimuli or memories. Secondarily, to examine the influence of baseline neuroendocrinological response, baseline…